Evidence map›Paper›PMID 31470851›Full record

ReviewCardiovascular diabetology2019

Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review.

Justyna Pordzik, Daniel Jakubik, Joanna Jarosz-Popek, Zofia Wicik, Ceren Eyileten, Salvatore De Rosa, Ciro Indolfi, Jolanta M Siller-Matula, Pamela Czajka, Marek Postula

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Transcriptomic Profile of LinBMC genomics · 2024
    Article
  18. Review
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Justyna PordzikDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.ORCID 0000-0002-3513-141X
Daniel JakubikDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.
Joanna Jarosz-PopekDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.
Zofia WicikRheumatology Division, Hospital das Clinicas HCFMUSP, University of São Paulo, School of Medicine, Av. Dr. Arnaldo, 455, Sao Paulo, SP, 01246-903, Brazil.
Ceren EyiletenDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.
Salvatore De RosaDivision of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, Viale Europa, 88100, Catanzaro, Italy.
Ciro IndolfiDivision of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, Viale Europa, 88100, Catanzaro, Italy.
Jolanta M Siller-MatulaDepartment of Cardiology, Medical University of Vienna, Vienna, Austria.
Pamela CzajkaDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.
Marek PostulaDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland. mpostula@wum.edu.pl.
Medical University of Warsaw · PLMagna Graecia University · ITHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the light of growing global epidemic of type 2 diabetes mellitus (T2DM), significant efforts are made to discover next-generation biomarkers for early detection of the disease. Multiple mechanisms including inflammatory response, abnormal insulin secretion and glucose metabolism contribute to the development of T2DM. Platelet activation, on the other hand, is known to be one of the underlying mechanisms of atherosclerosis, which is a common T2DM complication that frequently results in ischemic events at later stages of the disease. Available data suggest that platelets contain large amounts of microRNAs (miRNAs) that are found in circulating body fluids, including the blood. Since miRNAs have been illustrated to play an important role in metabolic homeostasis through regulation of multiple genes, they attracted substantial scientific interest as diagnostic and prognostic biomarkers in T2DM. Various miRNAs, as well as their target genes are implicated in the complex pathophysiology of T2DM. This article will first review the different miRNAs studied in the context of T2DM and platelet reactivity, and subsequently present original results from bioinformatic analyses of published reports, identifying a common gene (PRKAR1A) linked to glucose metabolism, blood coagulation and insulin signalling and targeted by miRNAs in T2DM. Moreover, miRNA-target gene interaction networks built upon Gene Ontology information from electronic databases were developed. According to our results, miR-30a-5p, miR-30d-5p and miR-30c-5p are the most widely regulated miRNAs across all specified ontologies, hence they are the most promising biomarkers of T2DM to be investigated in future clinical studies.

Indexed as

Computational BiologyBlood GlucoseBlood PlateletsCirculating MicroRNACyclic AMP-Dependent Protein Kinase RIalpha SubunitDatabases, GeneticDiabetes Mellitus, Type 2Gene Expression RegulationGene Regulatory NetworksGenetic MarkersHumansPlatelet ActivationProtein Interaction MapsBlood GlucoseCirculating MicroRNACyclic AMP-Dependent Protein Kinase RIalpha SubunitGenetic MarkersPRKAR1A protein, humanBioinformatic analysisBiomarkerDiabetes mellitus type 2DiagnosisMicroRNAmiRNA–gene target interactionPlatelet reactivityPrognosis

Identifiers

PMID31470851
PMCPMC6716825
OpenAlexW2970050196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.